Edwards Lifesciences
EW
$84.37
-2.77%
Edwards Lifesciences Corp is a global leader in structural heart disease medical devices, specializing in surgical tissue heart valves, transcatheter aortic valve replacement (TAVR), and transcatheter mitral and tricuspid therapies. The company holds a dominant market position in TAVR, with a strong pipeline and a global footprint, deriving about 60% of sales from outside the US. The current investor narrative centers on the potential for expanded Medicare coverage for TAVR procedures, which could significantly broaden the addressable market, alongside robust demand for its innovative heart valve therapies, as evidenced by a recent beat-and-raise quarter. The stock is also under scrutiny for its growth sustainability amid competitive pressures and regulatory developments.…
EW
Edwards Lifesciences
$84.37
Related headlines
EW 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Edwards Lifesciences's 12-month outlook, with a consensus price target around $100.96 and implied upside of +19.7% versus the current price.
Average Target
$100.96
0 analysts
Implied Upside
+19.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$84 - $110
Analyst target range
Edwards Lifesciences is covered by 26 analysts, with a consensus recommendation of 'Buy' and a mean rating of 1.62 (where 1 is Strong Buy and 5 is Sell). The average target price is $100.96, implying an upside of 12.3% from the current price of $89.90. The distribution includes 10 analysts with Buy or Outperform ratings and 2 with Hold, indicating a bullish sentiment. The high target of $110.00 suggests potential for further upside, while the low target of $84.00 implies a downside risk of 6.6%.
EW Technical Analysis
Edwards Lifesciences is in a clear uptrend, with the stock price at $89.90 as of September 4, 2026, up 11.04% over the past year. The current price sits at 88.6% of its 52-week range (between $72.30 low and $96.29 high), indicating the stock is trading near its highs, reflecting strong momentum but also potential overextension. The 52-week low of $72.30 was set in March 2026, and since then the stock has rallied, showing a sustained recovery from that trough.
Beta
0.85
0.85x market volatility
Max Drawdown
-13.2%
Largest decline past year
52-Week Range
$72-$96
Price range past year
Annual Return
+8.2%
Cumulative gain past year
| Period | EW Return | S&P 500 |
|---|---|---|
| 1m | -9.3% | -1.1% |
| 3m | -0.9% | +3.0% |
| 6m | +3.1% | +15.4% |
| 1y | +8.2% | +16.2% |
| ytd | -1.1% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EW Fundamental Analysis
Edwards Lifesciences reported Q1 2026 revenue of $1,648.6 million, a 16.7% year-over-year increase, accelerating from the 11.0% growth seen in Q1 2025. The growth is driven by strong performance in Transcatheter Heart Valves, which generated $1,197.3 million in revenue, and Transcatheter Mitral and Tricuspid Therapies at $175.1 million. This acceleration suggests robust demand for its TAVR and emerging therapies, supporting the investment thesis of sustained growth.
Quarterly Revenue
$1.6B
2026-03
Revenue YoY Growth
+16.7%
YoY Comparison
Gross Margin
78.2%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EW Overvalued?
Given that Edwards Lifesciences is profitable with a trailing net income of $380.7 million in Q1 2026, the primary valuation metric selected is the PE ratio. The trailing PE is 46.33x, while the forward PE is 26.62x, indicating the market expects significant earnings growth. The gap between trailing and forward PE suggests that the market is pricing in a substantial increase in EPS, which is consistent with the company's growth trajectory and the potential for expanded TAVR access.
PE
46.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 27x~51x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.3x
Enterprise Value Multiple